Explore the latest research on glaucoma treatment and the role of immune cells in eye pressure regulation for better outcomes ...

Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San ...

Add Yahoo as a preferred source to see more of our stories on Google. “The term glaucoma refers to a group of diseases that cause permanent damage to the optic nerve, which is the cable that connects ...

Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyFirst ...

Artelo Biosciences (ARTL) stock jumped 40% after announcing a fully-funded glaucoma trial for ART27.13 with Belfast Health and Social Care Trust.

Glaucoma is a devastating eye disease that currently affects more than 3 million Americans. By the year 2050, data shows the number of cases is projected to surge to more than 6 million cases. This is ...

Glaucoma is the term for a group of eye conditions that damage the optic nerve at the back of the eye. Without treatment, it can lead to vision loss and blindness. Glaucoma is not a life threatening ...

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...

When the eye's drainage system clogs, pressure builds up and causes damage. The pressure can lead to glaucoma and vision loss. New research, published in the journal Immunity, reveals that a ...

Dr Laila Raman-Abdulla, an ophthalmologist, is urging residents to prioritise regular eye examinations this March as part of World Glaucoma Month. The global awareness campaign aims to educate the ...